HF
MRKR icon

HRT Financial’s Marker Therapeutics MRKR Stock Holding History

HRT Financial’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Sell
11,852
-2,085
-15% -$3.31K ﹤0.01% 3597
2025
Q4 		$20K Buy
+13,937
New +$15.8K ﹤0.01% 2982
2023
Q3 		– Sell
-12,469
Closed -$38K – 2832
2023
Q2 		$38K Buy
+12,469
New +$21.7K ﹤0.01% 2042
2021
Q4 		– Sell
-4,922
Closed -$83K – 3740
2021
Q3 		$83K Buy
4,922
+365
+8% +$7.48K ﹤0.01% 2947
2021
Q2 		$127K Buy
+4,557
New +$120K ﹤0.01% 2535

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HRT Financial's MRKR Position: Q1 2026 in Review

HRT Financial reduced its Marker Therapeutics (MRKR) stake by 15% in Q1 2026, selling an estimated $3.31K and leaving 11,852 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #3597.

HRT Financial first reported a position in MRKR in Q2 2021 and has held it in 5 quarters since. The position peaked at $127K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • HRT Financial held 11,852 shares of Marker Therapeutics worth $15K as of Q1 2026.
  • HRT Financial sold 2,085 Marker Therapeutics shares in Q1 2026, an estimated $3.31K.
  • Marker Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3597 holding.
  • HRT Financial first reported a position in Marker Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • HRT Financial's Marker Therapeutics position peaked at $127K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.